# **Bioconjugate** Chemistry

# Enhanced DNA Binding and Photocleavage Abilities of $\beta$ -Cyclodextrin Appended Ru(II) Complex through Supramolecular Strategy

Ni Cheng,<sup>†</sup> Yong Chen,<sup>\*,†</sup> Jie Yu,<sup>†</sup> Jing-jing Li,<sup>†</sup> and Yu Liu<sup>\*,†,‡</sup>

<sup>†</sup>College of Chemistry, State Key Laboratory of Elemento-Organic Chemistry and <sup>‡</sup>Collaborative Innovation Center of Chemical Science and Engineering, Nankai University, Tianjin 300071, P. R. China

Supporting Information

ABSTRACT: Photosensitizers with high photocleavage ability are urgently needed to improve photodynamic therapy efficacy. Herein, a supramolecular complex was constructed through host-guest selfassembly using hexa- $\beta$ -CD-appended ruthenium polypyridyl (6CD-Ru) and adamantane-modified anthracene (ADA-AN) in water. The targeted DNA-intercalation of peripheral anthracenes can remarkably enhance photocleavage ability and antitumor activity of the complex irradiated with visible light.



hotodynamic therapy (PDT), a light-activated chemotherapeutic treatment, has emerged as a more effective and safer approach toward cancer therapy.<sup>1,2</sup> This treatment utilizes the excited state photosensitizer (PS) to generate cytotoxic reactive oxygen species (ROS) including singlet oxygen <sup>1</sup>O<sub>2</sub> through energy transfer to the 3O2.3,4 Subsequently ROS can react with the intracellular components such as DNA and lead to cancer cell necrosis and/or apoptosis.<sup>5</sup> Recently, a series of inorganic Ru(II), organometallic Ru(II), and nanomaterial Ru(II) complexes have been synthesized and developed.<sup>6</sup> Ru(II) polypyridyl complexes are among the most studied metal complexes in PDT. Due to their high population of triplet metal-to-ligand charge-transfer state (<sup>3</sup>MLCT) and large  $^{1}O_{2}$  yields, these compounds have been intensively applied as cytotoxic agents in PDT pathways.7 A series of functionalized Ru(II) polypyridyl complexes have been synthesized to design new metal-based anticancer drugs.<sup>8,9</sup> The Ru(II)-polypyridyl compound TLD-1433 has entered into the phase IB clinical trials as a PDT PS in 2015.8

However, in order to further improve PDT efficacy, Ru(II) systems that can locate at intracellular targets and exhibit multiple pathways of reactivity are highly sought. One approach is to covalently append polycyclic aromatic hydrocarbons on Ru(II) PSs,' such as anthracene, which can intercalate into the DNA double helix through the  $\pi$ -intercalation of grooves of DNA.<sup>10</sup> Meanwhile, anthracene groups are able to trap  ${}^{1}O_{2}$ and the obtained endoperoxides frequently release <sup>1</sup>O<sub>2</sub> under heating or UV irradiation, and thus oxidize adjacent sites in the DNA molecule.<sup>11–13</sup> Through covalently appending anthracene units with Ru(II)-polypyridyl complexes, Mariappan<sup>14</sup> and

Winkel<sup>15</sup> have found that anthracene could enhance the PDT reactivity of Ru(II) complexes. However, owing to their limited water solubility, these complexes usually possess no more than two polycyclic aromatic, which hinder the further advance for PDT.

Supramolecular chemistry provides a facile and rapid procedure to construct complicated molecular assemblies through noncovalent interactions. Of all macrocyclic host molecules, cyclodextrins (CDs) have attracted great attention for their natural availability, benign water solubility, biological compatibility, and low toxicity.<sup>16</sup> A number of host-guest supramolecular systems based on CDs have been reported for applications in biomedical science.<sup>17,18</sup> Very recently, Mao's group have constructed tumor-targeted metallo-anticancer agents using  $\beta$ -CD modified ruthenium-complex and adamantane-functionalized peptide through inclusion interaction.<sup>19</sup>

With the goal of targeted binding, then photocleavage toward DNA, herein, we presented a supramolecular strategy to construct a complex using hexa  $\beta$ -CD appended ruthenium polypyridyl (6CD-Ru) with adamantane-modified anthracene (ADA-AN) and investigated its abilities toward DNA binding and photocleavage (see Scheme 1). The constructed complex possesses inherent advantages as (1) the good water solubility through the appended CD moieties and the formation of the host-guest complexes between adamantane and CD, and (2) the six anthracene groups jointly enhance the DNA binding

```
Received: March 15, 2018
Revised:
          May 15, 2018
Published: May 29, 2018
```

Scheme 1. Schematic Representation of Intercalation and Photocleavage of DNA Using the Constructed Complex



strength, then facilitate the photocleavage ability of the (Ru) core when irradiated with visible light.

6CD-Ru and ADA-AN were obtained according to our previous reports.<sup>20,21</sup> Through the strong host–guest interaction between  $\beta$ -CD and adamantane group, ( $K_{\rm S} = 8 \times 10^4$  M<sup>-1</sup>),<sup>21</sup> we constructed a water-soluble supramolecular complex by mixing 6CD-Ru and 6 equiv ADA-AN in H<sub>2</sub>O. The fluorescence titration data were analyzed to estimate the binding constant ( $K_{\rm b}$ ) of the complex toward ctDNA. As shown in Figure 1, the fluorescence intensity of anthracene decreases



**Figure 1.** Fluorescence spectra of the complex with increasing concentration of ctDNA (0.0–6.0  $\mu$ M), [ADA-AN] = 3.75  $\mu$ M,  $\lambda_{ex}$  = 366 nm. Inset: Stem-Volmer quenching plot with increasing concentration of ctDNA, monitoring at 415 nm.

obviously with increasing concentration of ctDNA, indicating the intercalative binding of the anthryl group into the DNA helix.<sup>22</sup> The  $K_b$  value was obtained as  $2.5 \times 10^5$  M<sup>-1</sup> according to the Stern–Volmer equation.<sup>23</sup> By monitoring the absorption in UV–vis titration experiment (Figure S1), the  $K_b$  value was estimated to be  $8.6 \times 10^5$  M<sup>-1</sup> (Figure S2), which is in reasonable agreement with the result from fluorescence titration within the experimental error, lending credibility to these measurements.  $K_b$  value of the complex is one order greater than monomer ADA-AN<sup>21</sup> and other anthracene derivatives reported in the literature.<sup>15,23</sup> This can be attributed to the six anthracene units connected on one core (Ru), which could enhance the binding ability through multiple biding sites toward DNA. The complex is hence expected to enhance photocleavage ability.

More convincing evidence for the interaction mode of the complex with ctDNA comes from the displacement experiments using ethidium bromide (EB), a fluorescence dye that can intercalate with DNA duplex. As shown in Figure S3, with the addition of the complex to the EB/ctDNA solution, the EB fluorescence was obviously quenched, possibly because the intercalated EB was excluded out by the anthryl group in the complex.<sup>24</sup> This phenomenon confirms the intercalation binding mode of the complex toward DNA.

Circular dichroic (CD) spectral techniques can reveal how the conformation of the DNA chain is affected by the bound complex. As shown in Figure 2, the CD spectrum of free



Figure 2. Circular dichroism of free ctDNA, complex, and their mixtures in aqueous solution, [ctDNA] = 0.1 mM, [Ru] = 2  $\mu$ M.

ctDNA is composed of two major peaks, one negative peak at 247 nm attributed to helicity and one positive peak at 280 nm ascribed to base stacking. These characteristic spectra are consistent with double helical DNA in a right-handed B form.<sup>21</sup> The changes of these signals were observed in the presence of the complex. As shown in Figure 2, the positive band split into two, one at 258 nm with greater intensity and one at 274 nm with decreased intensity. The greater intensity could be ascribed to a partial B to A-DNA conformational transition, whereas the decreased intensity is due to base destacking as anthracene intercalation. Similar spectral changes were reported when intercalation occurred.<sup>25,26</sup> The more winding helix of A-DNA is reflected in the enhanced intensity of the negative band at 247 nm. These significant changes in the conformation of ctDNA indicate strong DNA-intercalation ability of the complex.

Agarose-gel electrophoresis was used to monitor the conversion of pBR322 DNA with different molar concentrations of the complex. Control runs (Figure 3, Lane 1) suggested that cleavage of pBR322 DNA in the absence of complex was not significant, where the plasmid was mainly in the supercoiled form (form I) with only a small amount of nicked impurity (form II). After keeping the mixtures under irradiation at 450 nm for 1 h, the complex showed concentration-dependent cleavage abilities (Lanes 2–5). As displayed in Figure 3, supercoiled DNA could be completely photocleaved in the presence of 2.7  $\mu$ M [Ru] ([ADA-AN] =

## **Bioconjugate Chemistry**



**Figure 3.** pBR322 DNA (150 ng) + complex: Lanes 1-5 ([Ru] = 0, 0.7, 1.3, 2.0, 2.7  $\mu$ M), upon irradiation at 450  $\pm$  5 nm for 1 h; Lanes 6–10, solutions with concentrations corresponding to 1–5 but kept in the dark for 1 h in each case.

16.2  $\mu$ M). The gradual loss of form I with no increase in form II in lanes 4–5 is due to the presence of DNA fragments after photocleavage, which is smaller than form III DNA and difficult to detect in the agarose-gel electrophoresis.<sup>27,28</sup>

In the dark control experiments, no obvious DNA cleavage was observed, whether or not it was treated with the complex (lanes 6–10). In the parallel control experiments, no clear DNA cleavage was observed even at 27  $\mu$ M of monomer 6CD-Ru (Figure S4), and complete photocleavage was not observed until 112  $\mu$ M of monomer ADA-AN upon irradiation (Figure S5). Compared with monomer compound 6CD-Ru and ADA-AN, the complex displayed improved cleavage ability by 1 order of magnitude toward supercoiled DNA. The large difference in cleavage ability can be attributed to the synergistic effect of core (Ru) and ADA-AN.

In attempts to unravel the probable mechanisms of the complex toward DNA photocleavage, control experiments were conducted through addition of various scavengers of the reactive oxygen. Sodium azide  $(NaN_3)$  and L-histidine could act as  ${}^{1}O_2$  scavengers, DMSO and NaI as hydroxyl radicals (·OH) scavengers, superoxide dismutase (SOD) as superoxide anion radical  $(O_2^{--})$ , and catalase as  $H_2O_2$  scavengers, respectively. As shown in Figure 4, obvious inhibitions were observed in the



**Figure 4.** Effect of "inhibitors" on the nuclease activity of complex. pBR322 DNA in the dark (Lane 1), upon irradiation (Lane 2); Lanes 3–8: pBR322 DNA with complex in the presence of L-histidine, NaN<sub>3</sub>, DMSO, NaI, SOD, and catalase, respectively, irradiation at 450  $\pm$  5 nm for 1 h in each case. [DNA] = 150 ng, [Ru] = 2.7  $\mu$ M.

presence of NaN<sub>3</sub>, NaI, and to a lesser extent by L-histidine, DMSO scavengers. These findings suggest that  ${}^{1}O_{2}$  and  $\cdot OH$  together act as ROS in light-induced DNA cleavage. Systems exhibiting multiple reactivities are desirable for PDT agents in order to improve PDT efficacy.<sup>29</sup>

To further confirm the formation of ROS in the complex system, EPR spin-trapping experiments were carried out in the presence of DMPO or TEMP. Upon irradiation at 450 nm, the characteristic EPR spectra for the DMPO-OH adducts<sup>30</sup> with a 1:2:2:1 quadruple signal with  $a_N = a_H = 14.9$  G were observed in Figure 5a. In addition, a 1:1:1 triplet characteristic signal of TEMPO (with  $a_N = 16.0$  G) was observed in Figure 5b, attributed to the adduct of  ${}^1O_2$  and TEMP.<sup>31</sup> These resulting paramagnetic products confirm the production of  ${}^1O_2$  and  $\cdot$ OH in the system.

To investigate the specific cellular targeting of the complex, the cellular uptake was confirmed by colocalization assays. The confocal microscopy images in Figure 6 reveal that the complex overlapped well with the commercial nuclear dye acridine orange (AO) in human lung carcinoma A549 cells. This result demonstrates that the complex can effectively penetrate the nuclear membrane and are mainly accumulated within the nuclear.

A549 cell was employed as the model cell to evaluate the in vitro cytotoxicity of the complex. The dark and light cytotoxicity profiles are given in Figure 7. After incubation with the complex in the dark for 24 h, the dose-dependent antitumor activity was clearly observed. A possible reason may be that the specific intercalation of anthracene units on the complex toward the DNA, as B to A-DNA conformational changes (Figure 2) could prevent DNA duplication and transcription to mRNA.<sup>26,32</sup> After irradiation at  $450 \pm 5$  nm for 10 min, the complex displayed better anticancer activity, as the relative cell mortality rate could be dramatically enhanced over that without irradiation. The phototoxic complex could annihilate 95% of the cancer cell population at concentration 8  $\mu$ M after PDT treatment. The half maximal inhibitory concentration  $(IC_{50})$  after PDT treatment was determined to be as low as 2.8  $\mu$ M (Figure S6), which is considerably lower compared to photofrin,<sup>33</sup> cisplatin,<sup>34</sup> and other ruthenium base photosensitizer,<sup>19,35,36</sup> indicating greatly enhanced cellular toxicity of the complex.

The production of intracellular ROS by the complex under irradiation was probed using ROS probe 2',7'-dichlorofluor-escein diacetate (DCFH-DA). Upon DCFH-DA being oxidized



Figure 5. EPR spectra of the trapped radical adducts (a) DMPO and (b) TEMP obtained upon irradiation of the complex at [Ru] = 0.5 mM, at 450  $\pm$  5 nm for 1 h in each case.



**Figure 6.** Determination of colocalization of the complex with AO by confocal microscopy. A549 cells were incubated with the complex (2  $\mu$ M, 24 h), and then stained with AO (10  $\mu$ g/mL, 30 min) at 37 °C. The concentration of the complex is based on the content of Ru(II) in solution.



Figure 7. Cytotoxicity experiments results of A549 cells treated with complex at various concentrations in the dark and after irradiation (450 nm, 10 min). The concentrations were calculated based on Ru(II) concentration.

to 2',7'-dichlorofluorescein (DCF) by ROS, it could be converted from a nonfluorescent to highly fluorescent state. Flow cytometric analysis (Figure S7) reveals a concentrationdependent fluorescent increase of DCF in A549 cells treated with the complex, which demonstrates that the enhanced cell death in Figure 7 induced by the complex under irradiation is mediated by ROS. Based on the above results, we speculated that both the intercalated binding toward DNA and the production of ROS under irradiation induce antitumor activity of the complex.

In summary, benefiting from the highly noncovalent binding, a promising DNA photocleavage supramolecular complex was successfully fabricated using 6CD-Ru and ADA-AN in aqueous solution. This complex can be accumulated in the nuclei of cancer cells. The presence of six anthracene intercalative groups in one assembly increased the affinity of the complex for DNA; thus, targeted delivery of ROS to the DNA was achieved. Consequently the supramolecular assembly exhibited excellent photoinduced DNA cleavage activity and efficient anticancer activity. This strategy presents a new opportunity for the construction of highly efficient photosensitizer in photodynamic therapy.

# ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.bioconj-chem.8b00191.

Instrumentation, methods, and characterization (PDF)

#### AUTHOR INFORMATION

#### **Corresponding Authors**

\*E-mail: yuliu@nankai.edu.cn.

\*E-mail: chenyong@nankai.edu.cn.

# ORCID 0

Yu Liu: 0000-0001-8723-1896

#### Notes

The authors declare no competing financial interest.

# ACKNOWLEDGMENTS

We thank NNSFC (21432004, 21672113, 21772099, 21861132001, and 91527301) for financial support.

#### REFERENCES

(1) Zhao, J., Wu, W., Sun, J., and Guo, S. (2013) Triplet Photosensitizers: From Molecular Design to Applications. *Chem. Soc. Rev.* 42, 5323–5351.

(2) Liu, J. N., Bu, W., and Shi, J. (2017) Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia. *Chem. Rev.* 117, 6160–6224.

(3) Chakrabortty, S., Agrawalla, B. K., Stumper, A., Vegi, N. M., Fischer, S., Reichardt, C., Kögler, M., Dietzek, B., Feuring-Buske, M., Buske, C., et al. (2017) Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications. J. Am. Chem. Soc. 139, 2512–2519.

(4) Dolmans, D. E. J. G. J., Fukumura, D., and Jain, R. K. (2003) Photodynamic Therapy for Cancer. *Nat. Rev. Cancer* 3, 380–387.

(5) Fan, W., Huang, P., and Chen, X. (2016) Overcoming the Achilles' Heel of Photodynamic Therapy. *Chem. Soc. Rev.* 45, 6488–6519.

(6) Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., and Chen, Z.-S. (2017) The Development of Anticancer Ruthenium(II) Complexes: From Single Molecule Compounds to Nanomaterials. *Chem. Soc. Rev.* 46, 5771–5804.

(7) Mari, C., Pierroz, V., Ferrari, S., and Gasser, G. (2015) Combination of Ru(II) Complexes and Light: New Frontiers in Cancer Therapy. *Chem. Sci. 6*, 2660–2686.

(8) Heinemann, F., Karges, J., and Gasser, G. (2017) Critical Overview of the Use of Ru(II) Polypyridyl Complexes as Photosensitizers in One-Photon and Two-Photon Photodynamic Therapy. *Acc. Chem. Res.* 50, 2727–2736.

(9) Meier-Menches, S. M., Gerner, C., Berger, W., Hartinger, C. G., and Keppler, B. K. (2018) Structure-Activity Relationships for Ruthenium and Osmium Anticancer Agents - Towards Clinical Development. *Chem. Soc. Rev.* 47, 909–928.

(10) Zhang, Y. H., Zhang, Y. M., Yang, Y., Chen, L. X., and Liu, Y. (2016) Controlled DNA Condensation and Targeted Cellular Imaging by Ligand Exchange in a Polysaccharide-Quantum Dot Conjugate. *Chem. Commun.* 52, 6087–6090.

(11) Aubry, J. M., Pierlot, C., Rigaudy, J., and Schmidt, R. (2003) Reversible Binding of Oxygen to Aromatic Compounds. *Acc. Chem. Res.* 36, 668–675.

## **Bioconjugate Chemistry**

(12) Asadirad, A. M., Erno, Z., and Branda, N. R. (2013) Photothermal Release of Singlet Oxygen from Gold Nanoparticles. *Chem. Commun.* 49, 5639–5641.

(13) Kolemen, S., Ozdemir, T., Lee, D., Kim, G. M., Karatas, T., Yoon, J., and Akkaya, E. U. (2016) Remote-Controlled Release of Singlet Oxygen by the Plasmonic Heating of Endoperoxide-Modified Gold Nanorods: Towards a Paradigm Change in Photodynamic Therapy. *Angew. Chem., Int. Ed.* 55, 3606–3610.

(14) Mariappan, M., and Maiya, B. G. (2005) Effects of Anthracene and Pyrene Units on the Interactions of Novel Polypyridylruthenium-(II) Mixed-Ligand Complexes with DNA. *Eur. J. Inorg. Chem.* 2005, 2164–2173.

(15) Padilla, R., Rodriguez-Corrales, J. A., Donohoe, L. E., Winkel, B. S. J., and Brewer, K. J. (2016) A New Class of Ru(II) Polyazine Agents with Potential for Photodynamic Therapy. *Chem. Commun. 52*, 2705–2708.

(16) Yu, G., Jie, K., and Huang, F. (2015) Supramolecular Amphiphiles Based on Host–Guest Molecular Recognition Motifs. *Chem. Rev.* 115, 7240–7303.

(17) Yu, J., Zhang, Y.-M., Li, P.-Y., and Liu, Y. (2017) Efficient Energy Transfer between Coronene-Modified Permethyl- $\beta$ -Cyclodextrins and Porphyrin for Light Induced DNA Cleavage. *Chem. Commun.* 53, 3717–3720.

(18) Yu, J., Chen, Y., Zhang, Y. H., Xu, X., and Liu, Y. (2016) Supramolecular Assembly of Coronene Derivatives for Drug Delivery. *Org. Lett.* 18, 4542–4545.

(19) Xue, S. S., Tan, C.-P., Chen, M.-H., Cao, J. J., Zhang, D. Y., Ye, R. R., Ji, L. N., and Mao, Z. W. (2017) Tumor-Targeted Supramolecular Nanoparticles Self-Assembled from a Ruthenium- $\beta$ -Cyclodextrin Complex and an Adamantane-Functionalized Peptide. *Chem. Commun.* 53, 842–845.

(20) Liu, Y., Chen, Y., Li, B., Wada, T., and Inoue, Y. (2001) Cooperative Multipoint Recognition of Organic Dyes by Bis( $\beta$ -Cyclodextrin)S with 2,2'-Bipyridine-4,4'-Dicarboxy Tethers. *Chem.* - *Eur. J.* 7, 2528–2535.

(21) Zhao, D., Chen, Y., and Liu, Y. (2014) Construction and DNA Condensation of Cyclodextrin-Coated Gold Nanoparticles with Anthryl Grafts. *Chem. - Asian J. 9*, 1895–1903.

(22) Inclán, M., Albelda, M. T., Frías, J. C., Blasco, S., Verdejo, B., Serena, C., Salat-Canela, C., Díaz, M. L., García-España, A., and García-España, E. (2012) Modulation of DNA Binding by Reversible Metal-Controlled Molecular Reorganizations of Scorpiand-Like Ligands. *J. Am. Chem. Soc.* 134, 9644–9656.

(23) Kumar, C. V., and Asuncion, E. H. (1993) DNA Binding Studies and Site Selective Fluorescence Sensitization of an Anthryl Probe. *J. Am. Chem. Soc.* 115, 8547–8553.

(24) Li, G. Y., Guan, R. L., Ji, L. N., and Chao, H. (2014) DNA Condensation Induced by Metal Complexes. *Coord. Chem. Rev.* 281, 100–113.

(25) Ivanov, V. I., Minchenkova, L. E., Schyolkina, A. K., and Poletayev, A. I. (1973) Different Conformations of Double-Stranded Nucleic Acid in Solution as Revealed by Circular Dichroism. *Biopolymers* 12, 89–110.

(26) Agudelo, D., Bourassa, P., Bérubé, G., and Tajmir-Riahi, H. A. (2014) Intercalation of Antitumor Drug Doxorubicin and Its Analogue by DNA Duplex: Structural Features and Biological Implications. *Int. J. Biol. Macromol.* 66, 144–150.

(27) Schneider, J. E., Browning, M. M., Zhu, X., Eneff, K. L., and Floyd, R. A. (1989) Characterization of Hydroxyl Free Radical Mediated Damage to Plasmid Pbr322 DNA. *Mutat. Res., Fundam. Mol. Mech. Mutagen.* 214, 23–31.

(28) Chitrapriya, N., Shin, J. H., Hwang, I. H., Kim, Y., Kim, C., and Kim, S. K. (2015) Synthesis, DNA Binding Profile and DNA Cleavage Pathway of Divalent Metal Complexes. *RSC Adv. 5*, 68067–68075.

(29) Sun, Y., Joyce, L. E., Dickson, N. M., and Turro, C. (2010) Efficient DNA Photocleavage by  $[Ru(Bpy)^2(Dppn)]^{2+}$  with Visible Light. *Chem. Commun.* 46, 2426–2428.

(30) Qi, C., Liu, X., Ma, J., Lin, C., Li, X., and Zhang, H. (2016) Activation of Peroxymonosulfate by Base: Implications for the Degradation of Organic Pollutants. *Chemosphere 151*, 280–288.

(31) Chen, Y., Lei, W., Jiang, G., Hou, Y., Li, C., Zhang, B., Zhou, Q., and Wang, X. (2014) Fusion of Photodynamic Therapy and Photoactivated Chemotherapy: A Novel Ru(II) Arene Complex with Dual Activities of Photobinding and Photocleavage toward DNA. *Dalton T. 43*, 15375–15384.

(32) Bowden, G. T., Roberts, R., Alberts, D. S., Peng, Y. M., and Garcia, D. (1985) Comparative Molecular Pharmacology in Leukemic L1210 Cells of the Anthracene Anticancer Drugs Mitoxantrone and Bisantrene. *Cancer. Res.* 45, 4915–4920.

(33) Delaey, E., van Laar, F., De Vos, D., Kamuhabwa, A., Jacobs, P., and de Witte, P. (2000) A Comparative Study of the Photosensitizing Characteristics of Some Cyanine Dyes. *J. Photochem. Photobiol., B 55*, 27–36.

(34) Wong, E. L.-M., Fang, G. S., Che, C. M., and Zhu, N. (2005) Highly Cytotoxic Iron(II) Complexes with Pentadentate Pyridyl Ligands as a New Class of Anti-Tumor Agents. *Chem. Commun.*, 4578–4580.

(35) Zeng, L., Kuang, S., Li, G., Jin, C., Ji, L., and Chao, H. (2017) A Gsh-Activatable Ruthenium(II)-Azo Photosensitizer for Two-Photon Photodynamic Therapy. *Chem. Commun.* 53, 1977–1980.

(36) Zhu, J., Rodriguez-Corrales, J. A., Prussin, R., Zhao, Z., Dominijanni, A., Hopkins, S. L., Winkel, B. S. J., Robertson, J. L., and Brewer, K. J. (2017) Exploring the Activity of a Polyazine Bridged Ru(II)-Pt(II) Supramolecule in F98 Rat Malignant Glioma Cells. *Chem. Commun.* 53, 145–148.